drugset / Trial / NCT01747746
Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.
Timeline
- Start
- 2012-10
- Primary completion
- 2014-10
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rivaroxaban | Other / unclassified | 20 mg | — |
| Background | Enoxaparin sodium | Other / unclassified | 1 mg/kg | — |
| Background | Enoxaparin sodium | Other / unclassified | 1.5 mg/kg | — |
| Background | Warfarin | Small molecule | 1 mg | — |
| Background | Warfarin | Small molecule | 10 mg | — |